Replies to post #105693 on Biotech Values

[DewDiligence]

JNJ/CRXL agreement now completed per PR.

Only if CRXL’s shareholders tender at least 80% of the outstanding shares.

[DewDiligence]

Largest CRXL shareholder other than JNJ continues to oppose buyout terms:

http://www.reuters.com/article/idCNLDE6961VU20101007

Van Herk, which is Crucell's second-biggest shareholder with a 10.02 percent stake, on Thursday said Crucell's stand-alone value should be 27.50 euros per share and it would ask Crucell management to convene a shareholder meeting to discuss the bid.

€27.50 is 11% higher than JNJ’s offer of €24.75.